Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Bradley L. Campbell M.B.A. | CEO, President & Director | 1.44M | 1.31M | 1976 |
| Mr. Simon Nicolas Reade Harford | Chief Financial Officer | 573.06k | -- | 1960 |
| Ms. Ellen S. Rosenberg J.D. | Chief Legal Officer & Corporate Secretary | 896.29k | 309.81k | 1963 |
| Mr. David M. Clark | Chief People Officer | 849.24k | -- | 1976 |
| Dr. Jeffrey P. Castelli Ph.D. | Chief Development Officer | 855.86k | -- | 1972 |
| Ms. Samantha Prout | Chief Accounting Officer & Controller | -- | -- | 1978 |
| Dr. Jill Weimer Ph.D. | Chief Science Officer | -- | -- | -- |
| Mr. Andrew Faughnan | Senior Director of Investor Relations | -- | -- | -- |
| Mr. Patrik S. Florencio Esq. | Global Chief Compliance & Risk Officer | -- | -- | -- |
| Ms. Diana Moore | Head of Global Corporate Communications | -- | -- | -- |
Amicus Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 500
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Corporate Governance
Upcoming Events
February 26, 2025 at 1:30 PM UTC - March 3, 2025 at 1:30 PM UTC
Amicus Therapeutics, Inc. Earnings Date